Company: XAIR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001493152-25-005678
Chunk: 105

Company: Beyond Air, Inc.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part II, Item 8
Chunk 105
---
 to the Company were repriced, to the extent such options had an exercise price in excess of $0.54,
the closing price per share of the Common Stock as reported on The Nasdaq Stock Market on November 22, 2024. As of the Effective
Date, all such options were repriced such that the exercise price per share was reduced to $0.54. Stock compensation costs of $1.4 million have been recognized in relation to this share re-price.

The
Company’s 2021 Beyond Cancer Ltd Equity Incentive Plan (the “2021 BC Plan”) allows for awards to officers, directors,
employees, and consultants of stock options, restricted stock units and restricted shares of Beyond Cancer’s common shares. The
vesting terms of the options issued under the 2021 BC Plan are generally four years and they expire ten
years from the grant date. On November 3, 2022, the Company’s Board of Directors approved an amendment to reserve for issuance an additional 2,000,000
shares of common stock. The 2021 BC Plan has
4,000,000
shares authorized for issuance. As of December
31, 2024, 713,000
common shares were available under the 2021 BC
Plan. 

 SCHEDULE
OF OPTION ACTIVITY

    Number of Options  
    Weighted Average Exercise Price of Options  
    Weighted Average Remaining Contractual Life of Options  
    Aggregate Intrinsic Value (thousands) 

    Options outstanding as of April 1, 2024 
     3,819,000  
    $5.50  
     8.3  
    $- 
  
    Granted 
     -  
     -  
     -  
     - 
  
    Exercised 
     -  
     -  
     -  
     - 
  
    Forfeited 
     (532,000) 
     5.50  
     -  
     - 
  
    Outstanding as of December 31, 2024 
     3,287,000  
    $5.50  
     7.5  
    $- 
  
    Exercisable as of December 31, 2024 
     2,097,000  
    $5.50  
     7.4  
    $